{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage+3&page=3", "query": { "condition": "Ovarian Cancer Stage 3", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 467, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage+3&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage+3&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T18:30:55.868Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00617929", "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2008-01", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617929" }, { "nct_id": "NCT00005956", "title": "Biological Therapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Gastric Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "HER-2/neu intracellular domain protein", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2000-02", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2014-07-09", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005956" }, { "nct_id": "NCT04498117", "title": "Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Ovarian Epithelial", "Ovarian Neoplasms", "Ovarian Cancer", "Ovarian Serous Adenocarcinoma", "Fallopian Tube Neoplasms", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Peritoneal Cancer", "Peritoneal Carcinoma", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Oregovomab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "CanariaBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 615, "start_date": "2020-08-25", "completion_date": "2028-08-26", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 81, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04498117" }, { "nct_id": "NCT04501913", "title": "Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8", "Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage 0 Gastric Cancer AJCC v8", "Clinical Stage I Esophageal Adenocarcinoma AJCC v8", "Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastric Cancer AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastric Cancer AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Hepatobiliary Neoplasm", "Malignant Digestive System Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Genitourinary System Neoplasm", "Malignant Neoplasm", "Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage 0 Gastric Cancer AJCC v8", "Pathologic Stage I Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage I Gastric Cancer AJCC v8", "Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IA Gastric Cancer AJCC v8", "Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IB Gastric Cancer AJCC v8", "Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage II Gastric Cancer AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIA Gastric Cancer AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIB Gastric Cancer AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Stage 0 Colorectal Cancer AJCC v8", "Stage 0a Bladder Cancer AJCC v8", "Stage 0is Bladder Cancer AJCC v8", "Stage I Bladder Cancer AJCC v8", "Stage I Cervical Cancer AJCC v8", "Stage I Colorectal Cancer AJCC v8", "Stage I Ovarian Cancer AJCC v8", "Stage I Prostate Cancer AJCC v8", "Stage I Renal Cell Cancer AJCC v8", "Stage I Uterine Corpus Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Ovarian Cancer AJCC v8", "Stage IA Uterine Corpus Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB Cervical Cancer AJCC v8", "Stage IB Ovarian Cancer AJCC v8", "Stage IB Uterine Corpus Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IB2 Cervical Cancer AJCC v8", "Stage IC Ovarian Cancer AJCC v8", "Stage II Bladder Cancer AJCC v8", "Stage II Cervical Cancer AJCC v8", "Stage II Colorectal Cancer AJCC v8", "Stage II Ovarian Cancer AJCC v8", "Stage II Prostate Cancer AJCC v8", "Stage II Renal Cell Cancer AJCC v8", "Stage II Uterine Corpus Cancer AJCC v8", "Stage IIA Cervical Cancer AJCC v8", "Stage IIA Colorectal Cancer AJCC v8", "Stage IIA Ovarian Cancer AJCC v8", "Stage IIA Prostate Cancer AJCC v8", "Stage IIA1 Cervical Cancer AJCC v8", "Stage IIA2 Cervical Cancer AJCC v8", "Stage IIB Cervical Cancer AJCC v8", "Stage IIB Colorectal Cancer AJCC v8", "Stage IIB Ovarian Cancer AJCC v8", "Stage IIB Prostate Cancer AJCC v8", "Stage IIC Colorectal Cancer AJCC v8", "Stage IIC Prostate Cancer AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-12-24", "completion_date": "2025-10-17", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501913" }, { "nct_id": "NCT02470585", "title": "Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasm" ], "interventions": [ { "name": "Veliparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Placebo to Veliparib", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1140, "start_date": "2015-07-14", "completion_date": "2023-10-05", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 135, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02470585" }, { "nct_id": "NCT01846520", "title": "Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy Subject", "Localized Transitional Cell Cancer of the Renal Pelvis and Ureter", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Psychosocial Effects of Cancer and Its Treatment", "Recurrent Bladder Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Gastric Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Uterine Sarcoma", "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter", "Stage II Bladder Cancer", "Stage II Renal Cell Cancer", "Stage II Urethral Cancer", "Stage IIA Cervical Cancer", "Stage IIA Colon Cancer", "Stage IIA Gastric Cancer", "Stage IIA Ovarian Epithelial Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIA Pancreatic Cancer", "Stage IIA Rectal Cancer", "Stage IIA Uterine Sarcoma", "Stage IIB Cervical Cancer", "Stage IIB Colon Cancer", "Stage IIB Gastric Cancer", "Stage IIB Ovarian Epithelial Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIB Pancreatic Cancer", "Stage IIB Rectal Cancer", "Stage IIB Uterine Sarcoma", "Stage IIC Colon Cancer", "Stage IIC Ovarian Epithelial Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage IIC Rectal Cancer", "Stage III Bladder Cancer", "Stage III Pancreatic Cancer", "Stage III Renal Cell Cancer", "Stage III Urethral Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Rectal Cancer", "Stage IIIA Uterine Sarcoma", "Stage IIIB Cervical Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Rectal Cancer", "Stage IIIB Uterine Sarcoma", "Stage IIIC Colon Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Rectal Cancer", "Stage IIIC Uterine Sarcoma", "Stage IV Bladder Cancer", "Stage IV Gastric Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Stage IV Urethral Cancer", "Stage IVA Cervical Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVA Uterine Sarcoma", "Stage IVB Cervical Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Stage IVB Uterine Sarcoma", "Ureter Cancer", "Stage IIA Lung Carcinoma", "Stage IIB Lung Carcinoma", "Stage IIIA Lung Carcinoma", "Stage IIIB Lung Carcinoma" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" }, { "name": "telephone-based intervention", "type": "BEHAVIORAL" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2013-10-29", "completion_date": "2019-05-23", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01846520" }, { "nct_id": "NCT04398446", "title": "Effect of Hemp-CBD on Patients With CIPN", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy-induced Peripheral Neuropathy", "Colorectal Cancer Stage II", "Colorectal Cancer Stage III", "Breast Cancer", "Ovarian Cancer", "Uterine Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Hemp-based CBD", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Main Line Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 56, "start_date": "2020-05-27", "completion_date": "2023-04-01", "has_results": false, "last_update_posted_date": "2022-09-01", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 1, "location_summary": "Wynnewood, Pennsylvania", "locations": [ { "city": "Wynnewood", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398446" }, { "nct_id": "NCT04550494", "title": "Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Castration-Resistant Prostate Carcinoma", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "HER2-Positive Breast Carcinoma", "Locally Advanced Breast Carcinoma", "Locally Advanced Gastric Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Ovarian Carcinoma", "Locally Advanced Pancreatic Carcinoma", "Locally Advanced Prostate Carcinoma", "Metastatic Breast Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Carcinoma", "Metastatic Prostate Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-04-26", "completion_date": "2027-07-27", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 4, "location_summary": "Gainesville, Florida • Bethesda, Maryland • Oklahoma City, Oklahoma", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04550494" }, { "nct_id": "NCT00023634", "title": "S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumors", "Gastric Cancer", "Ovarian Cancer", "Prostate Cancer" ], "interventions": [ { "name": "KLH", "type": "BIOLOGICAL" }, { "name": "GMCSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 14, "start_date": "2001-06", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 13, "location_summary": "Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more", "locations": [ { "city": "Bay City", "state": "Michigan" }, { "city": "Port Huron", "state": "Michigan" }, { "city": "Bellingham", "state": "Washington" }, { "city": "Bremerton", "state": "Washington" }, { "city": "Mount Vernon", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023634" }, { "nct_id": "NCT00293293", "title": "Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Cancer", "Peritoneal Primary Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "healing touch", "type": "OTHER" }, { "name": "massage therapy", "type": "OTHER" }, { "name": "hypnosis", "type": "OTHER" }, { "name": "Standard chemotherapy", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 43, "start_date": "2005-05", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-07T18:30:55.868Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00293293" } ] }